Europe Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023

List of Tables

The Europe Retinal Biologics Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030).

In both real-world situations and clinical trials, retinal biologics have been shown to produce better therapeutic results than conventional therapies. Patients and healthcare professionals find these therapies very appealing since they offer the potential to slow the advancement of the disease, enhance eyesight, and even reverse some of the consequences of retinal diseases. Typically, biological organisms like microbes, animal or plant cells, or other living entities are used to generate biologics. Retinal biologics are a novel class of drugs that work by aiming at particular indicators in the body of the patient to reduce the symptoms of various systemic or ocular conditions that manifest as eye problems.

Advances in biotechnology and an increase in the elderly population with retinal disorders are driving the market's expansion. Furthermore, retinal illnesses are more common among the elderly. Therefore, the aging population has raised the need for retinal biologic medicines and spurred market expansion.

According to estimates of European Blind Union (EBU), there are 30 million blind and partially sighted people living in Europe. On average, one in thirty Europeans experience vision loss, and the number of partially sighted people outnumbers the number of blind people by a factor of four. Women are more likely than men to go blind or partially blind. One in three seniors over the age of 65 has a visual loss, according to the EBU. 90% of those who are blind or visually impaired are older than 65. This greater estimate explains why it is challenging to determine with precision the prevalence of sight loss among Europe's aging population. Additionally, there are many people with various degrees of sight loss who choose not to report their illness due to ignorance or other personal factors. Consequently, such factors aid in the expansion of the market in the coming years.

The Germany market dominated the Europe Retinal Biologics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,153.2 million by 2030. The UK market is exhibiting a CAGR of 4.8% during (2023 - 2030). Additionally, The France market would experience a CAGR of 6.5% during (2023 - 2030).

Based on Indication, the market is segmented into Macular Degeneration, Diabetic Retinopathy and Others. Based on Drug Class, the market is segmented into VEGF-A Antagonist and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Amgen, Inc., AbbVie, Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., Santen Pharmaceutical Co., Ltd., Bausch Health Companies, Inc., F. Hoffmann-La Roche Ltd., MeiraGTx Holdings plc and Oxurion NV.

Scope of the Study

Market Segments covered in the Report:

By Indication

Macular Degeneration
Diabetic Retinopathy
Others

By Drug Class

VEGF-A Antagonist
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

By Country

Germany
UK
France
Russia
Spain
Italy
Rest of Europe

Companies Profiled

Novartis AG
Amgen, Inc.
AbbVie, Inc.
Bayer AG
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical Co., Ltd.
Bausch Health Companies, Inc.
F. Hoffmann-La Roche Ltd.
MeiraGTx Holdings plc
Oxurion NV

Unique Offerings from KBV Research

Exhaustive coverage
Highest number of market tables and figures
Subscription based model available
Guaranteed best price
Assured post sales research support with 10% customization free

Chapter 1. Market Scope & Methodology

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
- 1.4.1 Europe Retinal Biologics Market, by Indication
- 1.4.2 Europe Retinal Biologics Market, by Drug Class
- 1.4.3 Europe Retinal Biologics Market, by Distribution Channel
- 1.4.4 Europe Retinal Biologics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance

2.1 Key Highlights

Chapter 3. Market Overview

3.1 Introduction
- 3.1.1 Overview
  - 3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
- 3.2.1 Market Drivers
- 3.2.2 Market Restraints
3.3 Porter's Five Forces Analysis

Chapter 4. Strategies deployed in Retinal Biologics Market

Chapter 5. Europe Retinal Biologics Market by Indication

5.1 Europe Macular Degeneration Market by Country
5.2 Europe Diabetic Retinopathy Market by Country
5.3 Europe Others Market by Country

Chapter 6. Europe Retinal Biologics Market by Drug Class

6.1 Europe VEGF-A Antagonist Market by Country
6.2 Europe Others Market by Country

Chapter 7. Europe Retinal Biologics Market by Distribution Channel

7.1 Europe Hospital Pharmacy Market by Country
7.2 Europe Retail Pharmacy Market by Country
7.3 Europe Online Pharmacy Market by Country

Chapter 8. Europe Retinal Biologics Market by Country

8.1 Germany Retinal Biologics Market
- 8.1.1 Germany Retinal Biologics Market by Indication
- 8.1.2 Germany Retinal Biologics Market by Drug Class
- 8.1.3 Germany Retinal Biologics Market by Distribution Channel
8.2 UK Retinal Biologics Market
- 8.2.1 UK Retinal Biologics Market by Indication
- 8.2.2 UK Retinal Biologics Market by Drug Class
- 8.2.3 UK Retinal Biologics Market by Distribution Channel
8.3 France Retinal Biologics Market
- 8.3.1 France Retinal Biologics Market by Indication
- 8.3.2 France Retinal Biologics Market by Drug Class
- 8.3.3 France Retinal Biologics Market by Distribution Channel
8.4 Russia Retinal Biologics Market
- 8.4.1 Russia Retinal Biologics Market by Indication
- 8.4.2 Russia Retinal Biologics Market by Drug Class
- 8.4.3 Russia Retinal Biologics Market by Distribution Channel
8.5 Spain Retinal Biologics Market
- 8.5.1 Spain Retinal Biologics Market by Indication
- 8.5.2 Spain Retinal Biologics Market by Drug Class
- 8.5.3 Spain Retinal Biologics Market by Distribution Channel
8.6 Italy Retinal Biologics Market
- 8.6.1 Italy Retinal Biologics Market by Indication
- 8.6.2 Italy Retinal Biologics Market by Drug Class
- 8.6.3 Italy Retinal Biologics Market by Distribution Channel
8.7 Rest of Europe Retinal Biologics Market
- 8.7.1 Rest of Europe Retinal Biologics Market by Indication
- 8.7.2 Rest of Europe Retinal Biologics Market by Drug Class
- 8.7.3 Rest of Europe Retinal Biologics Market by Distribution Channel

Chapter 9. Company Profiles

9.1 Novartis AG
- 9.1.1 Company Overview
- 9.1.2 Financial Analysis
- 9.1.3 Segmental and Regional Analysis
- 9.1.4 Research & Development Expense
- 9.1.5 Recent strategies and developments:
  - 9.1.5.1 Acquisition and Mergers:
- 9.1.6 SWOT Analysis
9.2 Amgen, Inc.
- 9.2.1 Company Overview
- 9.2.2 Financial Analysis
- 9.2.3 Regional Analysis
- 9.2.4 Research & Development Expenses
- 9.2.5 SWOT Analysis
9.3 AbbVie, Inc.
- 9.3.1 Company Overview
- 9.3.2 Financial Analysis
- 9.3.3 Regional Analysis
- 9.3.4 Research & Development Expense
- 9.3.5 Recent strategies and developments:
  - 9.3.5.1 Partnerships, Collaborations, and Agreements:
  - 9.3.5.2 Approvals & Trials:
- 9.3.6 SWOT Analysis
9.4 Bayer AG
- 9.4.1 Company Overview
- 9.4.2 Financial Analysis
- 9.4.3 Segmental and Regional Analysis
- 9.4.4 Research & Development Expense
- 9.4.5 SWOT Analysis
9.5 Regeneron Pharmaceuticals, Inc.
- 9.5.1 Company Overview
- 9.5.2 Financial Analysis
- 9.5.3 Research & Development Expense
- 9.5.4 SWOT Analysis
9.6 Santen Pharmaceutical Co., Ltd.
- 9.6.1 Company Overview
- 9.6.2 Financial Analysis
- 9.6.3 Regional Analysis
- 9.6.4 Research & Development Expenses
- 9.6.5 SWOT Analysis
9.7 Bausch Health Companies, Inc.
- 9.7.1 Company Overview
- 9.7.2 Financial Analysis
- 9.7.3 Segmental and Regional Analysis
- 9.7.4 Research & Development Expense
- 9.7.5 Recent strategies and developments:
  - 9.7.5.1 Partnerships, Collaborations, and Agreements:
  - 9.7.5.2 Approvals & Trials:
  - 9.7.5.3 Acquisition and Mergers:
- 9.7.6 SWOT Analysis
9.8 F. Hoffmann-La Roche Ltd.
- 9.8.1 Company Overview
- 9.8.2 Financial Analysis
- 9.8.3 Segmental and Regional Analysis
- 9.8.4 Research & Development Expense
- 9.8.5 Recent strategies and developments:
  - 9.8.5.1 Partnerships, Collaborations, and Agreements:
  - 9.8.5.2 Approvals & Trials:
- 9.8.6 SWOT Analysis
9.9 MeiraGTx Holdings plc
- 9.9.1 Company Overview
- 9.9.2 Financial Analysis
- 9.9.3 Research & Development Expenses
- 9.9.4 SWOT Analysis
9.10. Oxurion NV
- 9.10.1 Company Overview
- 9.10.2 Financial Analysis
- 9.10.3 Research & Development Expenses
- 9.10.4 SWOT Analysis

LIST OF TABLES

TABLE 1 Europe Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 2 Europe Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 3 Europe Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 4 Europe Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 5 Europe Macular Degeneration Market by Country, 2019 - 2022, USD Million
TABLE 6 Europe Macular Degeneration Market by Country, 2023 - 2030, USD Million
TABLE 7 Europe Diabetic Retinopathy Market by Country, 2019 - 2022, USD Million
TABLE 8 Europe Diabetic Retinopathy Market by Country, 2023 - 2030, USD Million
TABLE 9 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 10 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 11 Europe Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 12 Europe Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 13 Europe VEGF-A Antagonist Market by Country, 2019 - 2022, USD Million
TABLE 14 Europe VEGF-A Antagonist Market by Country, 2023 - 2030, USD Million
TABLE 15 Europe Others Market by Country, 2019 - 2022, USD Million
TABLE 16 Europe Others Market by Country, 2023 - 2030, USD Million
TABLE 17 Europe Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 Europe Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 Europe Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 Europe Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 Europe Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 Europe Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 Europe Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 Europe Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 Europe Retinal Biologics Market by Country, 2019 - 2022, USD Million
TABLE 26 Europe Retinal Biologics Market by Country, 2023 - 2030, USD Million
TABLE 27 Germany Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 28 Germany Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 29 Germany Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 30 Germany Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 31 Germany Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 32 Germany Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 33 Germany Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Germany Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 UK Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 36 UK Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 37 UK Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 38 UK Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 39 UK Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 40 UK Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 41 UK Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 UK Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 France Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 44 France Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 45 France Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 46 France Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 47 France Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 48 France Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 49 France Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 France Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Russia Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 52 Russia Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 53 Russia Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 54 Russia Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 55 Russia Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 56 Russia Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 57 Russia Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Russia Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 Spain Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 60 Spain Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 61 Spain Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 62 Spain Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 63 Spain Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 64 Spain Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 65 Spain Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 Spain Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Italy Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 68 Italy Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 69 Italy Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 70 Italy Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 71 Italy Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 72 Italy Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 73 Italy Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Italy Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of Europe Retinal Biologics Market, 2019 - 2022, USD Million
TABLE 76 Rest of Europe Retinal Biologics Market, 2023 - 2030, USD Million
TABLE 77 Rest of Europe Retinal Biologics Market by Indication, 2019 - 2022, USD Million
TABLE 78 Rest of Europe Retinal Biologics Market by Indication, 2023 - 2030, USD Million
TABLE 79 Rest of Europe Retinal Biologics Market by Drug Class, 2019 - 2022, USD Million
TABLE 80 Rest of Europe Retinal Biologics Market by Drug Class, 2023 - 2030, USD Million
TABLE 81 Rest of Europe Retinal Biologics Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of Europe Retinal Biologics Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information - Novartis AG
TABLE 84 Key Information - Amgen, Inc.
TABLE 85 Key information - AbbVie, Inc.
TABLE 86 Key Information - Bayer AG
TABLE 87 Key Information - Regeneron Pharmaceuticals, Inc.
TABLE 88 Key Information - Santen Pharmaceutical Co., Ltd.
TABLE 89 key information - Bausch Health Companies, Inc.
TABLE 90 KEY INFORMATION - F. Hoffmann-La Roche Ltd.
TABLE 91 Key Information - MeiraGTx Holdings plc
TABLE 92 Key Information - Oxurion NV

List of Figures

FIG 1 Methodology for the research
FIG 2 Europe Retinal Biologics Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Retinal Biologics Market
FIG 4 Porter's Five Forces Analysis - Retinal Biologics Market
FIG 5 Europe Retinal Biologics Market share by Indication, 2022
FIG 6 Europe Retinal Biologics Market share by Indication, 2030
FIG 7 Europe Retinal Biologics Market by Indication, 2019 - 2030, USD Million
FIG 8 Europe Retinal Biologics Market share by Drug Class, 2022
FIG 9 Europe Retinal Biologics Market share by Drug Class, 2030
FIG 10 Europe Retinal Biologics Market by Drug Class, 2019 - 2030, USD Million
FIG 11 Europe Retinal Biologics Market share by Distribution Channel, 2022
FIG 12 Europe Retinal Biologics Market share by Distribution Channel, 2030
FIG 13 Europe Retinal Biologics Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 Europe Retinal Biologics Market share by Country, 2022
FIG 15 Europe Retinal Biologics Market share by Country, 2030
FIG 16 Europe Retinal Biologics Market by Country, 2019 - 2030, USD Million
FIG 17 SWOT Analysis: Novartis AG
FIG 18 Swot Analysis: Amgen, Inc.
FIG 19 Swot Analysis: AbbVie, Inc.
FIG 20 Swot Analysis: Bayer AG
FIG 21 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 22 Swot Analysis: Santen Pharmaceutical Co., Ltd.
FIG 23 Recent strategies and developments: Bausch Health Companies, Inc.
FIG 24 Swot Analysis: Bausch Health Companies, Inc.
FIG 25 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 26 Swot Analysis: MeiraGTx Holdings plc
FIG 27 Swot Analysis: Oxurion NV

Europe Retinal Biologics Market Size, Share & Industry Trends Analysis Report By Indication (Macular Degeneration, Diabetic Retinopathy), By Drug Class (VEGF-A Antagonist and Others), By Distribution Channel, By Country and Growth Forecast, 2023 - 2030

Description

Table of Contents